-

EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement Therapy

LONDON--(BUSINESS WIRE)--Theramex, a global company specialised in women's health, announced today the Decentralised Procedure approval in several EU countries and the UK of BIJUVA® (1 mg estradiol / 100 mg progesterone) capsules for the indication of continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.

"Up to 80% of women experience vasomotor symptoms during their menopause transition,1, 2 and these lasted more than 7 years for more than half of the women. 3 With Bijuva, Theramex aims to help these patients with an oral combination of low dose estradiol and progesterone which have the same chemical and molecular structure as the hormones produced naturally in a woman’s body", says Robert Stewart, CEO of the company.

Bijuva is the first and only oral combined HRT with bio-identical hormones, made available to patients across Europe through the license agreement that TherapeuticsMD (Nasdaq: TXMD) and Theramex signed in June 2019 granting Theramex the exclusive license and supply agreement to commercialize BIJUVA outside the United States, Canada and Israel.

About Theramex

Theramex is a leading, global specialty pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at every stage of their lives. Theramex’s commitment is to understand its patients, serve their needs, and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective solutions that care for and support women as they advance through each stage of their lives. To learn more about Theramex, please visit www.theramex.com.

References:

  1. Woods NF, Mitchell ES. Am J Med. 2005;118(suppl 12B):14–24.
  2. Gold EB, Colvin A, Avis N, et al. Am J Public Health. 2006;96(7):1226–1235.
  3. Avis NE et al JAMA Intern Med. 2015 Apr 1; 175(4): 531–539. 

Contacts

For any enquiries, please contact:
Nicholas Saunders, Director - Global Menopause Franchise
Nicholas.Saunders@theramex.com

Industry:

Theramex

Release Versions
EnglishSpanishGermanFrenchItalianDutchPolish

Contacts

For any enquiries, please contact:
Nicholas Saunders, Director - Global Menopause Franchise
Nicholas.Saunders@theramex.com

Social Media Profiles
theramex/Linkedin
More News From Theramex

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals. “As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatm...

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil

LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingd...

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women’s health. The EC decision follows the Committee for Medicinal P...
Back to Newsroom